The efficacy endpoint for the trial is deep response rate, defined as CR plus PRs of greater than 50% tumor volume reduction ... it has demonstrated immunomodulatory activity resulting in activation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback